Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214465 | 0.88 | LMNA (0.41) | LMNAHSD17B10ALDH1A1KDM4CTSHR | |
| SCHEMBL6730282 | 0.77 | ALDH1A1 (0.38) | LMNAHSD17B10ALDH1A1KDM4CTDP1 | |
| SCHEMBL6730280 | 0.72 | KDM4C (0.37) | LMNAHSD17B10ALDH1A1KDM4CCYP2D6 | |
| SCHEMBL23770097 | 0.71 | LMNA (0.41) | LMNAHSD17B10ALDH1A1KDM4CTSHR | |
| SCHEMBL21813306 | 0.70 | CYP2D6 (0.37) | CYP2D6CYP2C19 | |
| SCHEMBL10900663 | 0.69 | CYP2D6 (0.36) | CYP2D6CYP2C19 | |
| SCHEMBL10426442 | 0.68 | ALDH1A1 (0.35) | ALDH1A1KDM4C | |
| SCHEMBL1934610 | 0.67 | — | — | |
| SCHEMBL6729276 | 0.66 | SMN1; SMN2 (0.38) | LMNAHSD17B10ALDH1A1KDM4CTSHR | |
| SCHEMBL23173503 | 0.65 | TDP1 (0.44) | LMNAHSD17B10ALDH1A1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | LMNA 4298/4885HSD17B10 243/4885ALDH1A1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.